Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Introducing the International Women in Multiple Sclerosis network.

Jokubaitis VG, Pröbstel AK, Arrambide G, Costello F, Waubant E.

Lancet Neurol. 2019 Jun;18(6):521. doi: 10.1016/S1474-4422(19)30160-7. No abstract available.

PMID:
31122489
2.

Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria.

Arrambide G, Tintore M, Montalban X.

Mult Scler. 2019 May 16:1352458519846103. doi: 10.1177/1352458519846103. [Epub ahead of print] No abstract available.

PMID:
31094275
3.

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.

Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, Galán I, Río J, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez B, Midaglia L, Mulero P, Mitjana R, Auger C, Sastre-Garriga J, Montalban X, Tintoré M.

Neurology. 2019 Mar 26;92(13):e1507-e1516. doi: 10.1212/WNL.0000000000007178. Epub 2019 Mar 1.

4.

Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease.

Pedreño M, Sepúlveda M, Armangué T, Sabater L, Martínez-Hernandez E, Arrambide G, Blanco Y, Llufriu S, Martínez-Lapiscina EH, Mulero P, Sola-Valls N, Ruiz-García R, Tintoré M, Dalmau J, Graus F, Saiz A.

Mult Scler Relat Disord. 2019 Feb;28:230-234. doi: 10.1016/j.msard.2019.01.007. Epub 2019 Jan 3.

PMID:
30623863
5.

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.

Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X.

Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. No abstract available.

PMID:
30587519
6.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.

PMID:
29462277
7.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

8.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.

Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

PMID:
28984163
9.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2018 May;24(6):721-727. doi: 10.1177/1352458517707070. Epub 2017 Apr 26.

PMID:
28445084
10.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2018 Mar;24(3):301-312. doi: 10.1177/1352458517697830. Epub 2017 Mar 16.

PMID:
28301287
11.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2018 Mar;24(3):322-330. doi: 10.1177/1352458517698052. Epub 2017 Mar 13.

PMID:
28287331
12.

Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".

Arrambide G.

Mult Scler. 2017 Mar;23(3):486-487. doi: 10.1177/1352458516675752. Epub 2016 Nov 12. No abstract available.

PMID:
28260414
13.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X.

Neurology. 2016 Sep 27;87(13):1368-74. doi: 10.1212/WNL.0000000000003144. Epub 2016 Aug 26.

PMID:
27566747
14.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

15.

Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A.

J Neurol. 2016 Jul;263(7):1349-60. doi: 10.1007/s00415-016-8147-7. Epub 2016 May 4.

16.

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun.

17.

CSF examination still has value in the diagnosis of MS - Commentary.

Arrambide G, Tintore M.

Mult Scler. 2016 Jul;22(8):997-8. doi: 10.1177/1352458516642033. Epub 2016 Apr 8. No abstract available.

PMID:
27059063
18.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.

Arrambide G, Espejo C, Tintore M.

Mult Scler. 2015 Sep;21(10):1240-2. doi: 10.1177/1352458515589774. Epub 2015 Aug 4. No abstract available.

PMID:
26242692
19.

Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X.

Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21.

PMID:
25902415
20.

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, Comabella M, Nos C, Galán I, Vidal-Jordana A, Simon E, Castilló J, Palavra F, Mitjana R, Auger C, Rovira À, Montalban X.

Mult Scler. 2015 Dec;21(14):1802-10. doi: 10.1177/1352458515575338. Epub 2015 Mar 16.

PMID:
25778697
21.

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.

Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M.

Brain. 2015 Apr;138(Pt 4):918-31. doi: 10.1093/brain/awv017. Epub 2015 Feb 13.

PMID:
25688078
22.

Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.

Arrambide G, Tur C, Montalban X.

Mult Scler. 2015 Apr;21(5):660-1. doi: 10.1177/1352458514551457. Epub 2015 Feb 6. No abstract available.

PMID:
25662350
23.

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X.

Mult Scler. 2015 May;21(6):780-5. doi: 10.1177/1352458514549401. Epub 2014 Nov 12.

PMID:
25392320
24.

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.

Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Calvo AC, Olascoaga J, Ramió-Torrentà L, Reindl M, Benito-León J, Casanova B, Arrambide G, Sabater L, Graus F, Dalmau J, Saiz A.

Mult Scler. 2015 Jun;21(7):866-874. doi: 10.1177/1352458514555785. Epub 2014 Oct 24.

25.

NMO spectrum disorders: how wide is the spectrum?

Arrambide G, Rovira A, Tur C, Montalban X.

Mult Scler. 2014 Sep;20(10):1417-9. doi: 10.1177/1352458514546517. No abstract available.

PMID:
25160127
26.

Predictive markers of disease evolution after a CIS in everyday practice.

Arrambide G, Sastre-Garriga J.

J Neurol Sci. 2014 Aug 15;343(1-2):8-14. doi: 10.1016/j.jns.2014.05.023. Epub 2014 May 20.

PMID:
24881867
27.

Early predictors of multiple sclerosis after a typical clinically isolated syndrome.

Ruet A, Arrambide G, Brochet B, Auger C, Simon E, Rovira A, Montalban X, Tintoré M.

Mult Scler. 2014 Nov;20(13):1721-6. doi: 10.1177/1352458514533397. Epub 2014 May 19.

PMID:
24842960
28.

Thrombotic thrombocytopenic purpura-haemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta.

Arrambide G.

Mult Scler. 2014 Nov;20(13):1788-9. doi: 10.1177/1352458514529614. Epub 2014 Apr 2. No abstract available.

PMID:
24696053
29.

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

Tur C, Tintoré M, Vidal-Jordana Á, Bichuetti D, Nieto González P, Arévalo MJ, Arrambide G, Anglada E, Galán I, Castilló J, Nos C, Río J, Martín MI, Comabella M, Sastre-Garriga J, Montalban X.

PLoS One. 2013 Dec 10;8(12):e82796. doi: 10.1371/journal.pone.0082796. eCollection 2013.

30.

Clinical impact of early brain atrophy in clinically isolated syndromes.

Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X.

Mult Scler. 2013 Dec;19(14):1878-86. doi: 10.1177/1352458513488231. Epub 2013 May 7.

PMID:
23652215
31.

Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis.

Arrambide G, Espejo C, Yarden J, Fire E, Spector L, Dotan N, Dukler A, Rovira A, Montalban X, Tintore M.

PLoS One. 2013;8(3):e59953. doi: 10.1371/journal.pone.0059953. Epub 2013 Mar 28.

32.

Hydroxylamido-amino acid complexes of oxovanadium(V). Toxicological study in cell culture and in a zebrafish model.

León IE, Di Virgilio AL, Barrio DA, Arrambide G, Gambino D, Etcheverry SB.

Metallomics. 2012 Dec;4(12):1287-96. doi: 10.1039/c2mt20091k.

PMID:
23073485
33.

Value of NMO-IgG determination at the time of presentation as CIS.

Costa C, Arrambide G, Tintore M, Castilló J, Sastre-Garriga J, Tur C, Río J, Saiz A, Vidal-Jordana A, Auger C, Nos C, Rovira A, Comabella M, Horga A, Montalban X.

Neurology. 2012 May 15;78(20):1608-11. doi: 10.1212/WNL.0b013e3182563b32. Epub 2012 May 2.

PMID:
22551725
34.

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.

Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.

Mult Scler. 2012 Aug;18(8):1193-6. doi: 10.1177/1352458512439238. Epub 2012 Mar 1.

PMID:
22383232
35.

A prospective series of patients with hyperglycaemia-associated movement disorders.

Cervantes-Arriaga A, Arrambide G, Rodríguez-Violante M.

J Clin Neurosci. 2011 Oct;18(10):1329-32. doi: 10.1016/j.jocn.2011.01.029. Epub 2011 Jul 23.

PMID:
21784643
36.

Brainstem lesions in clinically isolated syndromes.

Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, Nos C, Edo MC, Castilló J, Horga A, Perez-Miralles F, Huerga E, Comabella M, Sastre-Garriga J, Montalban X.

Neurology. 2010 Nov 23;75(21):1933-8. doi: 10.1212/WNL.0b013e3181feb26f.

PMID:
21098409
37.

Mental disorders in Mexican patients with multiple sclerosis.

Espinola-Nadurille M, Colin-Piana R, Ramirez-Bermudez J, Lopez-Gomez M, Flores J, Arrambide G, Corona T.

J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):63-9. doi: 10.1176/appi.neuropsych.22.1.63.

PMID:
20160211
38.

Spectroscopic behavior and biological activity of K2[VO(O2)NTA].2H2O.

Arrambide G, Barrio DA, Etcheverry SB, Gambino D, Baran EJ.

Biol Trace Elem Res. 2010 Aug;136(2):241-8. doi: 10.1007/s12011-009-8538-z. Epub 2009 Oct 20.

PMID:
19841872
39.

Early onset multiple sclerosis: the role of gender.

Tintoré M, Arrambide G.

J Neurol Sci. 2009 Nov 15;286(1-2):31-4. doi: 10.1016/j.jns.2009.07.016. Epub 2009 Aug 15.

PMID:
19683727
40.

Spectroscopic behavior and biological activity of K3[VO(O2)2CO3]∙H2O.

Arrambide G, Rivadeneira J, Etcheverry SB, Parajón-Costa BS, Gambino D, Baran EJ.

Biol Trace Elem Res. 2009 Dec;132(1-3):176-83. doi: 10.1007/s12011-009-8375-0.

PMID:
19396406
41.

Biological effects of a complex of vanadium(V) with salicylaldehyde semicarbazone in osteoblasts in culture: mechanism of action.

Rivadeneira J, Barrio DA, Arrambide G, Gambino D, Bruzzone L, Etcheverry SB.

J Inorg Biochem. 2009 Apr;103(4):633-42. doi: 10.1016/j.jinorgbio.2008.11.009. Epub 2008 Nov 28.

PMID:
19117608
42.

Design of vanadium mixed-ligand complexes as potential anti-protozoa agents.

Benítez J, Guggeri L, Tomaz I, Arrambide G, Navarro M, Pessoa JC, Garat B, Gambino D.

J Inorg Biochem. 2009 Apr;103(4):609-16. doi: 10.1016/j.jinorgbio.2008.10.018. Epub 2008 Nov 7.

PMID:
19091422
43.

Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium.

Urquiola C, Vieites M, Aguirre G, Marín A, Solano B, Arrambide G, Noblía P, Lavaggi ML, Torre MH, González M, Monge A, Gambino D, Cerecetto H.

Bioorg Med Chem. 2006 Aug 15;14(16):5503-9. Epub 2006 May 18.

PMID:
16709457

Supplemental Content

Loading ...
Support Center